Company Overview

Avacta (AIM: AVCT) is a UK-based company that specializes in proprietary diagnostic tools, consumables and reagents for life sciences.

It has developed the Affimer, an alternative to antibodies and aptamers, which is based on a small protein scaffold that can be engineered to bind with high specificity and affinity to a wide range of protein targets.

Affimer technology can be used for a wide range of applications in diagnostics, drug/biomarker discovery and biotech research & development. They can also act as therapeutic agents.In January 2020, Avacta and Korea's Daewoong Pharmaceutical formed an immunotherapy-focused joint venture to develop the next generation of cell and gene therapies incorporating Affimer proteins to enhance the immune-modulatory effects.